Stay updated with breaking news from Christopher Morten. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The fight over Medicare drug price negotiation picked back up this week with oral arguments in AstraZeneca’s lawsuit and the federal government sending out its first offers for a maximum fair price to manufacturers. AstraZeneca on Wednesday gave its first oral arguments in the District Court of Delaware. Like other companies and pharmaceutical entities, the…
The free market is not what it seems.
This past week in healthcare investigations
/cloudfront-ap-southeast-2.images.arcpublishing.com/nzme/XAHVFL5KJNEWNGXIENYNV4ANW4.jpg)
New York Times: Company devised plan to delay new drug’s release to maximise profits.
Today, a generation of expensive Gilead drugs containing the new iteration of tenofovir account for half of the market for HIV treatment and prevention, according to IQVIA, an industry data provider. One widely used product, Descovy, has a sticker price of $26,000 annually. Generic versions of its predecessor, Truvada, whose patents have expired, now cost less than $400 a year.